Literature DB >> 28066649

A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting.

Cesare Gridelli1, Tania Losanno2.   

Abstract

Entities:  

Year:  2016        PMID： 28066649      PMCID： PMC5179438          DOI： 10.21037/jtd.2016.11.91

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  28 in total

1.  Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.

Authors:  Jean-Charles Soria; Yi-Long Wu; Kazuhiko Nakagawa; Sang-We Kim; Jin-Ji Yang; Myung-Ju Ahn; Jie Wang; James Chih-Hsin Yang; You Lu; Shinji Atagi; Santiago Ponce; Dae Ho Lee; Yunpeng Liu; Kiyotaka Yoh; Jian-Ying Zhou; Xiaojin Shi; Alan Webster; Haiyi Jiang; Tony S K Mok
Journal:  Lancet Oncol       Date:  2015-07-06       Impact factor: 41.316

2.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Authors:  Roy S Herbst; Diane Prager; Robert Hermann; Lou Fehrenbacher; Bruce E Johnson; Alan Sandler; Mark G Kris; Hai T Tran; Pam Klein; Xin Li; David Ramies; David H Johnson; Vincent A Miller
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

3.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

4.  Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel.

Authors:  David B Solit; Yuhong She; Jose Lobo; Mark G Kris; Howard I Scher; Neal Rosen; Frank M Sirotnak
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

5.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Authors:  Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Vincent Miller; Ronald B Natale; Joan H Schiller; Joachim Von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

6.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

7.  Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells.

Authors:  Tianhong Li; Yi-He Ling; I David Goldman; Roman Perez-Soler
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

8.  Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

Authors:  Yi-Long Wu; Jin Soo Lee; Sumitra Thongprasert; Chong-Jen Yu; Li Zhang; Guia Ladrera; Vichien Srimuninnimit; Virote Sriuranpong; Jennifer Sandoval-Tan; Yunzhong Zhu; Meilin Liao; Caicun Zhou; Hongming Pan; Victor Lee; Yuh-Min Chen; Yan Sun; Benjamin Margono; Fatima Fuerte; Gee-Chen Chang; Kasan Seetalarom; Jie Wang; Ashley Cheng; Elisna Syahruddin; Xiaoping Qian; James Ho; Johan Kurnianda; Hsingjin Eugene Liu; Kate Jin; Matt Truman; Ilze Bara; Tony Mok
Journal:  Lancet Oncol       Date:  2013-06-17       Impact factor: 41.316

9.  The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.

Authors:  Shang-Gin Wu; Yi-Nan Liu; Meng-Feng Tsai; Yih-Leong Chang; Chong-Jen Yu; Pan-Chyr Yang; James Chih-Hsin Yang; Yueh-Feng Wen; Jin-Yuan Shih
Journal:  Oncotarget       Date:  2016-03-15

10.  First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.

Authors:  J-Y Douillard; G Ostoros; M Cobo; T Ciuleanu; R McCormack; A Webster; T Milenkova
Journal:  Br J Cancer       Date:  2013-11-21       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.